MP1-07 ENRICHMENT OF CIRCULATING TUMOR CELLS IN PATIENTS WITH LOCALIZED PROSTATE CANCER USING A MICROFLUIDIC DEVICE

The primary analysis endpoints were per-patient changes in treatment modalities, immediate and cumulative costs (2014 US currency), and ratio of changes in costs over changes in survival benefit adjusted for quality of life. RESULTS: With clinical assessment alone, 44% of patients selected AS following the initial diagnosis, which increased to 70% when adding GPS to clinical assessment. With greater use of AS, immediate treatment costs declined by $5,743; cumulative 5-year costs declined by $594. This assumes 5-year cost with AS monitoring of $4,913 and increased adherence to AS by a relative 23% per year with GPS. GPS is cost neutral if the probability of AS patients progressing to definitive treatment declines by at least a relative 10% per year with utilization of the assay. Lower costs were realized for all clinically assessed NCCN risk categories. The most sensitive inputs were initial and deferred costs of definitive treatment. CONCLUSIONS: Incorporating GPS into treatment decisions resulted in greater use of AS, and can reduce overall healthcare costs within 5 years. These findings should assist professional societies to further evaluate both the clinical and the economic impact of genomic tests in treatment decisions.